Cellares raised $257 million in a Series D extension to accelerate global expansion of its automated cell‑therapy manufacturing services and prepare for a planned 2027 public listing. The company intends to launch commercial manufacturing services for ex vivo cell therapies, positioning its automated platform as a solution to industry bottlenecks in capacity, reproducibility and cost. Investors signaled confidence in outsourced, scalable cell‑therapy production as demand from CAR‑T, TCR and other engineered cell programs grows. The financing will ramp facilities, regulatory readiness and customer onboarding to capture emerging demand from both biotechs and large pharma.